[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Hellebust et al., 2012 - Google Patents

Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics

Hellebust et al., 2012

View HTML
Document ID
7238398522859727868
Author
Hellebust A
Richards-Kortum R
Publication year
Publication venue
Nanomedicine

External Links

Snippet

Over the last three decades, our understanding of the molecular changes associated with cancer development and progression has advanced greatly. This has led to new cancer therapeutics targeted against specific molecular pathways; such therapies show great …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Hellebust et al. Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics
Chen et al. Near-infrared luminescence high-contrast in vivo biomedical imaging
Zhang et al. Recent advances in near-infrared II imaging technology for biological detection
Chinen et al. Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence
Pierce et al. Optical contrast agents and imaging systems for detection and diagnosis of cancer
Li et al. The application of nanoparticles in diagnosis and theranostics of gastric cancer
Li et al. Fluorescence-guided probes of aptamer-targeted gold nanoparticles with computed tomography imaging accesses for in vivo tumor resection
De Boer et al. Optical innovations in surgery
Luo et al. Mesoporous silica-coated gold nanorods with embedded indocyanine green for dual mode X-ray CT and NIR fluorescence imaging
Gunasekera et al. Imaging applications of nanotechnology in cancer
Etrych et al. Fluorescence optical imaging in anticancer drug delivery
Wojtynek et al. Image‐guided tumor surgery: The emerging role of nanotechnology
Li et al. Surface-enhanced Raman nanoparticles for tumor theranostics applications
Wang et al. Upconversion nanoparticles in biological labeling, imaging, and therapy
Luo et al. Quantum dots in cancer therapy
Kumar et al. Optical molecular imaging agents for cancer diagnostics and therapeutics
Keereweer et al. Image‐guided surgery in head and neck cancer: current practice and future directions of optical imaging
Kim et al. Development and in vivo imaging of a PET/MRI nanoprobe with enhanced NIR fluorescence by dye encapsulation
Akinfieva et al. New directions in quantum dot-based cytometry detection of cancer serum markers and tumor cells
Atreya et al. Molecular imaging in gastroenterology
Radenkovic et al. Quantum dot nanoparticle for optimization of breast cancer diagnostics and therapy in a clinical setting
He et al. Combination of fluorescence-guided surgery with photodynamic therapy for the treatment of cancer
Xin et al. Tracking tumor heterogeneity and progression with near‐infrared II fluorophores
Su et al. CuS as a gatekeeper of mesoporous upconversion nanoparticles-based drug controlled release system for tumor-targeted multimodal imaging and synergetic chemo-thermotherapy
Etrych et al. Fluorescence imaging as a tool in preclinical evaluation of polymer-based nano-DDS systems intended for cancer treatment